Form 4: Neurocrine Biosciences Director Stephen Sherwin Reports Stock Transactions
SEC Form 4 Filing
Director Stephen Sherwin reports acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.
Summary
- On May 22, 2025, Stephen Sherwin, a director of Neurocrine Biosciences Inc., reported transactions involving the company's stock.
- Sherwin acquired 3,318 Restricted Stock Units (RSUs) on May 21, 2025, which will vest in full on May 21, 2026.
- He also disposed of 2,869 shares of common stock on May 22, 2025.
- Following these transactions, Sherwin directly owns 3,318 derivative securities and 13,542 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock transactions, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is a common practice for publicly traded companies.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the actions of a company director.
Key Dates
| Date | Description |
|---|---|
| 05/21/2025 | Date of earliest transaction and acquisition of Restricted Stock Units. |
| 05/22/2025 | Date of common stock disposal and filing date of the Form 4. |
| 05/21/2026 | Date the acquired Restricted Stock Units will vest in full. |
Keywords
Neurocrine Biosciences, NBIX, Stephen Sherwin, Form 4, Stock Transaction, Restricted Stock Units, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.